ExThera Medical Corporation (ExThera) is developing revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections.
ExThera has developed a first-of-its-kind blood filter designed to capture and reduce a broad range of bacteria, viruses, toxins and pro-inflammatory cytokines from whole blood. Harmful substances are captured and adsorbed onto the device’s proprietary surface and are thereby reduced from the bloodstream without adding anything to the treated blood, which is then returned to the patient with blood cells intact.
The company is focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations.
Steven Opal, M.D. (Brown University) editorial in Critical Care highlights the need for non-antibiotic alternatives for treating pan-resistant bloodstream infections, referencing our work with Seraph.
ExThera Medical has completed a multi-center, non-randomized European trial for the Seraph® Microbind® Affinity Blood Filter (Seraph).